Search results for "10209 Clinic for Cardiology"

showing 10 items of 12 documents

Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression

2017

The P2Y12 antagonist ticagrelor reduces mortality in patients with acute coronary syndrome (ACS), compared with clopidogrel, and the mechanisms underlying this effect are not clearly understood. Arterial thrombosis is the key event in ACS; however, direct vascular effects of either ticagrelor or clopidogrel with focus on arterial thrombosis and its key trigger tissue factor have not been previously investigated.Methods and results: Human aortic endothelial cells were treated with ticagrelor or clopidogrel active metabolite (CAM) and stimulated with tumour necrosis factor-alpha (TNF-α); effects on procoagulant tissue factor (TF) expression and activity, its counter-player TF pathway inhibito…

0301 basic medicineMaleTicagrelorAdenosineTime FactorsPhysiology030204 cardiovascular system & hematology2737 Physiology (medical)0302 clinical medicineP2Y12AntithromboticCells CulturedClopidogrelReceptors Purinergic P2Y123. Good healthClopidogrelmedicine.anatomical_structureCoagulation10209 Clinic for CardiologyCardiologyCardiology and Cardiovascular MedicineTicagrelormedicine.drugBlood PlateletsAcute coronary syndromemedicine.medical_specialtyProteasome Endopeptidase ComplexTiclopidineEndotheliumDown-Regulation610 Medicine & health2705 Cardiology and Cardiovascular MedicineThromboplastinEquilibrative Nucleoside Transporter 103 medical and health sciencesTissue factorFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineAnimalsHumanscardiovascular diseasesBlood Coagulationbusiness.industryTumor Necrosis Factor-alphaEndothelial CellsThrombosis1314 Physiologymedicine.diseaseMice Inbred C57BLDisease Models Animal030104 developmental biologyProteolysisPurinergic P2Y Receptor AntagonistsbusinessCarotid Artery InjuriesPlatelet Aggregation Inhibitors
researchProduct

Takotsubo Syndrome: Impact of endothelial dysfunction and oxidative stress

2021

Takotsubo Syndrome (TTS) is characterized by a transient left ventricular dysfunction recovering spontaneously within days or weeks. Although the pathophysiology of TTS remains obscure, there is growing evidence suggesting TTS to be associated with increased production of reactive oxygen species (ROS), which may be involved in causing transient coronary and peripheral endothelial dysfunction leading to a transient impairment of myocardial contraction due to stunning (apical ballooning). Endothelial dysfunction is mainly caused by decreased vascular and myocardial nitric oxide bioavailability in response to increased ROS production. Accordingly, studies in humans and animal models demonstrat…

0301 basic medicinemedicine.medical_specialty1303 Biochemistry610 Medicine & healthSodium hydrosulfidemedicine.disease_causeBiochemistryNitric oxide03 medical and health scienceschemistry.chemical_compound2737 Physiology (medical)0302 clinical medicineSuperoxidesTakotsubo CardiomyopathyPhysiology (medical)Internal medicinemedicineAnimalsHumansEndothelial dysfunctionchemistry.chemical_classificationReactive oxygen speciesNADPH oxidasebiologySuperoxideNADPH OxidasesHydrogen PeroxideMalondialdehydemedicine.diseaseOxidative Stress030104 developmental biologyEndocrinologychemistry10209 Clinic for Cardiologybiology.proteinReactive Oxygen Species030217 neurology & neurosurgeryOxidative stressFree Radical Biology and Medicine
researchProduct

Endogenous peroxynitrite modulates PGHS-1–dependent thromboxane A2 formation and aggregation in human platelets

2008

Aggregation of activated platelets is considerably mediated by the autocrine action of thromboxane A2 (TxA2) which is formed in a prostaglandin endoperoxide H2 synthase-1 (PGHS-1 or COX-1)-dependent manner. The activity of PGHS-1 can be stimulated by peroxides, an effect termed "peroxide tone", that renders PGHS-1 the key regulatory enzyme in the formation of TxA2. Activated platelets release nitric oxide (*NO) and superoxide (O*2) but their interactions with the prostanoid pathway have been controversially discussed in platelet physiology and pathophysiology. The current study demonstrates that endogenously formed peroxynitrite at nanomolar concentrations, originating from the interaction …

1303 BiochemistryPlatelet AggregationSuperoxideProstanoid610 Medicine & healthBiochemistryNitric oxideCell biologychemistry.chemical_compoundPeroxynitrous acidThromboxane A2Thromboxane A22737 Physiology (medical)BiochemistrychemistryPhysiology (medical)Peroxynitrous Acid10209 Clinic for CardiologyCyclooxygenase 1Humanslipids (amino acids peptides and proteins)PlateletPlatelet activationPeroxynitrite
researchProduct

Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022)

2022

AbstractDyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowe…

Diabetes Mellitus Type 2 / diagnosisDyslipidemias / drug therapyEndocrinology Diabetes and Metabolism610 Medicine & health2705 Cardiology and Cardiovascular MedicineCardiovascular risk Diabetes Individual therapy approach Lipid lowering therapy StatinsHumansIndividual therapy approachDyslipidemiasHypolipidemic AgentsDiabetes Mellitus Type 2 / epidemiologyDiabetesStatinsCholesterol LDLCardiovascular riskAtherosclerosisDyslipidemias / diagnosis2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 22724 Internal MedicineDyslipidemias / epidemiology10209 Clinic for CardiologyProprotein Convertase 9Diabetes Mellitus Type 2 / drug therapyCardiology and Cardiovascular MedicineLipid lowering therapy
researchProduct

Improvement in Risk Stratification in Transcatheter Aortic Valve Implantation Using a Combination of the Tumor Marker CA125 and the Logistic EuroSCORE

2017

Conventional risk scores have not been accurate in predicting peri- and postprocedural risk of patients undergoing transcatheter aortic valve implantation (TAVI). Elevated levels of the tumor marker carbohydrate antigen 125 (CA125) have been linked to adverse outcomes after TAVI. We studied the additional value of CA125 to that of the EuroSCORE in predicting long-term mortality after TAVI.During a median follow-up of 59 weeks, 115 of 422 patients (27%) died after TAVI. Mortality was higher with elevated CA125 (30 U/mL) and EuroSCORE (median) (47% vs 20%, P.001 and 38% vs 16%, P.001, respectively). In the multivariable analysis, CA125 (30 U/mL) remained an independent predictor of mortality …

MaleLogistic euroscoremedicine.medical_specialtyPoor prognosisTranscatheter aortic610 Medicine & health030204 cardiovascular system & hematologyRisk AssessmentSeverity of Illness Index2705 Cardiology and Cardiovascular MedicineTranscatheter Aortic Valve Replacement03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineProspective Studies030212 general & internal medicineAgedTumor markerbusiness.industryHazard ratioMembrane ProteinsEuroSCOREAortic Valve StenosisGeneral MedicinePrognosisConfidence intervalCA-125 AntigenRisk stratification10209 Clinic for CardiologyCardiologyFemalebusinessRevista Española de Cardiología (English Edition)
researchProduct

New-generation drug-eluting stents for left main coronary artery disease according to the EXCEL trial enrollment criteria: Insights from the all-come…

2019

Percutaneous coronary intervention (PCI) has been established as an alternative treatment option to coronary artery by-pass graft (CABG) surgery in patients with left main coronary artery disease (LMCAD). Whether the findings of randomized controlled trials are applicable to a real-world patient population is unclear.We compared the outcomes of PCI with new-generation DES in the all-comer, international, multicenter DELTA-2 registry retrospectively evaluating mid-term clinical outcomes with the historical CABG cohort enrolled in the DELTA-1 registry according to the EXCEL key inclusion or exclusion criteria. The primary endpoint was the composite of death, myocardial infarction, or stroke a…

Malemedicine.medical_specialtyInternationalitymedicine.medical_treatmenteducationPopulation610 Medicine & healthCoronary Artery Disease030204 cardiovascular system & hematology2705 Cardiology and Cardiovascular Medicinelaw.inventionDELTA-2 registry; Drug-eluting stents; EXCEL trial; Left main coronary artery; Cardiology and Cardiovascular Medicine03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRandomized controlled triallawInternal medicineDELTA-2 registrymedicineClinical endpointHumanscardiovascular diseases030212 general & internal medicineMyocardial infarctionRegistriesMortalityeducationDrug-eluting stentsAgedRetrospective StudiesAged 80 and overeducation.field_of_studyProportional hazards modelbusiness.industryEXCEL trialHazard ratioPercutaneous coronary interventionLeft main coronary arteryMiddle Agedmedicine.diseasehumanitiessurgical procedures operativeConventional PCI10209 Clinic for CardiologyFemalebusinessCardiology and Cardiovascular Medicine
researchProduct

Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethality.

2019

Tissue factor is highly expressed in sub-endothelial tissue. The extracellular allosteric disulfide bond Cys186-Cys209 of human tissue factor shows high evolutionary conservation and in vitro evidence suggests that it significantly contributes to tissue factor procoagulant activity. To investigate the role of this allosteric disulfide bond in vivo, we generated a C213G mutant tissue factor mouse by replacing Cys213 of the corresponding disulfide Cys190-Cys213 in murine tissue factor. A bleeding phenotype was prominent in homozygous C213G tissue factor mice. Pre-natal lethality of 1/3rd of homozygous offspring was observed between E9.5 and E14.5 associated with placental hemorrhages. After b…

Malemedicine.medical_specialtyOffspring610 Medicine & healthHemorrhage030204 cardiovascular system & hematologyBiologymedicine.disease_causeArticleThromboplastin11459 Center for Molecular Cardiology03 medical and health sciencesTissue factorArterial Thrombosis; Blood Coagulation and Fibrinolysis; Disorders of Coagulation and FibrinolysisMice0302 clinical medicineIn vivoPregnancyInternal medicinemedicineExtracellularAnimalsDisulfidesMutationHematologyPhenotypeIn vitroEndocrinologyPhenotype10036 Medical Clinic10076 Center for Integrative Human PhysiologyHemostasisMutation10209 Clinic for CardiologyFemale030215 immunologyHaematologica
researchProduct

Percutaneous coronary intervention of chronic total occlusions in patients with low left ventricular ejection fraction

2017

Abstract Objectives The study sought to assess the outcome of percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) in patients with low left ventricular ejection fraction (LVEF) (≤35%). Background Data regarding the outcome of PCI in patients with low LVEF affected by CTO are scarcely reported. Methods The authors performed a prospective longitudinal multicenter study including consecutive patients undergoing elective PCI of CTOs. Patients were subdivided into 3 groups: group 1 (LVEF ≥50%), group 2 (LVEF 35% to 50%), and group 3 (LVEF ≤35%). Results A total of 839 patients (mean 64.6 ± 10.5 years of age, 87.7% men) underwent CTO PCI attempts. Baseline LVEF ≤35% was pr…

Malemedicine.medical_specialtyanimal structuresTime Factorsmedicine.medical_treatment610 Medicine & healthKaplan-Meier Estimate030204 cardiovascular system & hematologyCoronary AngiographyDisease-Free SurvivalVentricular Function Left2705 Cardiology and Cardiovascular Medicinechronic total occlusion; ischemic LV dysfunction; left ventricular ejection fraction; PCI; Cardiology and Cardiovascular Medicinechronic total occlusionischemic LV dysfunctionleft ventricular ejection fractionPCI03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRisk FactorsInternal medicinemedicineHumansIn patientcardiovascular diseases030212 general & internal medicineLongitudinal StudiesProspective Studieschronic total occlusionAgedProportional Hazards ModelsEjection fractionbusiness.industryPercutaneous coronary interventionleft ventricular ejection fractionPCIStroke VolumeRecovery of FunctionMiddle AgedSurgeryEuropeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseCardiology10209 Clinic for CardiologyFemalebusinessCardiology and Cardiovascular Medicineischemic LV dysfunction
researchProduct

Role of Chemerin in Cardiovascular Diseases.

2022

(1) Background: Obesity is closely connected to the pathophysiology of cardiovascular diseases (CVDs). Excess fat accumulation is associated with metabolic malfunctions that disrupt cardiovascular homeostasis by activating inflammatory processes that recruit immune cells to the site of injury and reduce nitric oxide levels, resulting in increased blood pressure, endothelial cell migration, proliferation, and apoptosis. Adipose tissue produces adipokines, such as chemerin, that may alter immune responses, lipid metabolism, vascular homeostasis, and angiogenesis. (2) Methods: We performed PubMed and MEDLINE searches for articles with English abstracts published between 1997 (when the first re…

adipokinechemerin receptorsMedicine (miscellaneous)610 Medicine & health2701 Medicine (miscellaneous)endothelial dysfunctionGeneral Biochemistry Genetics and Molecular Biologyadipokine cardiovascular disease chemerin chemerin receptors chemerin-targeting therapeutic agents endothelial dysfunction inflammation1300 General Biochemistry Genetics and Molecular Biologycardiovascular diseaseinflammation10209 Clinic for Cardiologychemerin-targeting therapeutic agentschemerinBiomedicines
researchProduct

Derivation and validation of a novel bleeding risk score for elderly patients with venous thromboembolism on extended anticoagulation

2017

SummaryExisting clinical scores do not perform well in predicting bleeding in elderly patients with acute venous thromboembolism (VTE). We sought to derive an easy-to-use clinical score to help physicians identify elderly patients with VTE who are at high-risk of bleeding during extended anticoagulation (>3 months). Our derivation sample included 743 patients aged ≥65 years with VTE who were enrolled in a prospective multicenter cohort study. All patients received extended anticoagulation with vitamin K antagonists. We derived our score using competing risk regression, with the time to a first major bleeding up to 36 months of extended anticoagulation as the outcome, and 17 candidate var…

medicine.medical_specialtyAnemia2720 Hematology610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciencesAnticoagulation0302 clinical medicineElderlyInternal medicineAnticoagulation; Bleeding risk; Elderly; HematologyBleeding riskmedicineDerivation030212 general & internal medicineInternal validation610 Medicine & healthddc:616Framingham Risk Scorebusiness.industry10031 Clinic for AngiologyCancerHematologymedicine.diseaseSurgery10209 Clinic for CardiologybusinessVenous thromboembolismMajor bleeding360 Social problems & social servicesCohort study
researchProduct